Acid Blue 92: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 19731 |
| CHEMBL ID | 2106378 |
| CHEMBL ID | 2362713 |
| MeSH ID | M0330277 |
| Synonym |
|---|
| sodium anazolene |
| cirene brilliant blue r |
| airedale blue rl |
| coomasdie blue rl |
| c.i. acid blue 92, trisodium salt |
| acid blue a |
| calcocid fast blue sr |
| cyanine acid blue r new |
| amacid fast blue r |
| acid blue 2k |
| fenazo blue sr |
| medium blue embl |
| anazolene sodium |
| benzyl blue r |
| cyanine acid blue r |
| sulphon acid blue ra |
| fast acid blue rl |
| hispacid fast blue r |
| sulphon acid blue r |
| tertracid fast blue sr |
| pontacyl fast blue r |
| c.i. 13390 |
| vondamol fast blue r |
| benzyl fast blue r |
| coomassie blue medicinal |
| acid blue 92 |
| sulfonine acid blue r |
| sulphon acid blue ra extra |
| acid leather blue r |
| acilan fast navy blue r |
| nsc-47734 |
| anazolene sodium (usan/inn) |
| D02936 |
| lampronol blue br |
| luxol fast blue ar |
| caracid cyanine blue r conc pdr |
| anazolene, sodium |
| mechasol blue rl |
| 4-((4-anilino-5-sulfo-1-naphthyl)azo)-5-hydroxy-2,7-naphthalenedisulfonic acid trisodium salt |
| c.i. acid blue 92 trisodium salt |
| suminol fast navy blue r |
| luxol fast blue arn |
| trisodium 4'-anilino-8-hydroxy-1,1'-azonaphthalene-3,6,5'-trisulfonate |
| acid fast blue r |
| 2,7-naphthalenedisulfonic acid, 4-((4-anilino-5-sulfo-1-naphthyl)azo)-5-hydroxy-, trisodium salt |
| 2,7-naphthalenedisulfonic acid, 4-hydroxy-5-((4-(phenylamino)-5-sulfo-1-naphthalenyl)azo)-, trisodium salt |
| anazolene sodium [usan:inn] |
| modr kysela 92 [czech] |
| best acid blue 3r |
| nsc 47734 |
| kayanol navy blue r |
| einecs 223-378-0 |
| anazoleno sodico [inn-spanish] |
| sodium anoxynaphthonate |
| trisodium 4-hydroxy-4-(4-anilino-5-sulphonato-1-naphthylazo)naphthalene-2,7-disulphonate |
| anazolenum natricum [inn-latin] |
| 2,7-naphthalenedisulfonic acid, 4-hydroxy-5-((4-(phenylamino)-5-sulfo-1-naphthalenyl)azo), trisodium salt |
| mechasol blue rlx |
| anazolene sodique [inn-french] |
| 3861-73-2 |
| dtxcid7026578 |
| dtxsid9046578 , |
| cas-3861-73-2 |
| tox21_112375 |
| AKOS024319585 |
| CHEMBL2106378 |
| luxol fate blue arn |
| modr kysela 92 |
| unii-f6g1k9wju4 |
| anazolene sodique |
| f6g1k9wju4 , |
| anazolenum natricum |
| 2,7-naphthalenedisulfonic acid, 4-hydroxy-5-(2-(4-(phenylamino)-5-sulfo-1-naphthalenyl)diazenyl)-, sodium salt (1:3) |
| AKOS015903012 |
| 4-[(4-anilino-5-sulfo-1-naphthyl)azo]-5-hydroxy-2,7-naphthalenedisulfonic acid trisodium salt |
| anazolene sodium [usan] |
| anazolene sodium [mi] |
| anazolene sodium [inn] |
| AKOS025310852 |
| 2,7-naphthalenedisulfonic acid, 4-hydroxy-5-[[4-(phenylamino)-5-sulfo-1-naphthalenyl]azo]-, trisodium salt |
| CHEMBL2362713 |
| luxol fast blue am |
| mfcd00003967 |
| trisodium;4-[(4-anilino-5-sulfonatonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonate |
| sodium (e)-4-hydroxy-5-((4-(phenylamino)-5-sulfonatonaphthalen-1-yl)diazenyl)naphthalene-2,7-disulfonate |
| c.i. acid blue 92 trisodium;l 451167 trisodium |
| anazolene (trisodium) |
| Q27277715 |
| D89343 |
| sodium 4-hydroxy-5-((4-(phenylamino)-5-sulfonatonaphthalen-1-yl)diazenyl)naphthalene-2,7-disulfonate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 16.0867 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 19.3720 | 0.0002 | 21.2231 | 8,912.5098 | AID743042; AID743054 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 16.8511 | 0.0002 | 29.3054 | 16,493.5996 | AID743079; AID743080; AID743091 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 16.7855 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 23.7101 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 23.2638 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 13.3332 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 13.3332 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| ATP binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| ATP hydrolysis activity | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| DNA clamp unloader activity | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| DNA binding | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| RNA binding | Ataxin-2 | Homo sapiens (human) |
| epidermal growth factor receptor binding | Ataxin-2 | Homo sapiens (human) |
| protein binding | Ataxin-2 | Homo sapiens (human) |
| mRNA binding | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| Elg1 RFC-like complex | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| nucleus | ATPase family AAA domain-containing protein 5 | Homo sapiens (human) |
| cytoplasm | Ataxin-2 | Homo sapiens (human) |
| Golgi apparatus | Ataxin-2 | Homo sapiens (human) |
| trans-Golgi network | Ataxin-2 | Homo sapiens (human) |
| cytosol | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| membrane | Ataxin-2 | Homo sapiens (human) |
| perinuclear region of cytoplasm | Ataxin-2 | Homo sapiens (human) |
| ribonucleoprotein complex | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347157 | Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347158 | ZIKV-mCherry secondary qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347156 | DAPI mCherry counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||